Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, has entered into a Global Framework Research Agreement with Lundbeck A/S, a leading international pharmaceutical company focused on the development of medications for central nervous system disorders.

This agreement will allow scientists at Lundbeck's global research locations to access Asterand's XpressBANK of human tissue and clinical data and the PhaseZERO drug discovery services platform to advance development of treatments for psychiatric and neurological disorders. Financial terms were not disclosed.

Martyn Coombs, CEO of Asterand commented, "We are honoured that Lundbeck has chosen Asterand as a preferred human tissue solutions provider. As we seek avenues to create closer relationships with our key clients, this extended collaboration provides Asterand with the opportunity to assist Lundbeck in its quest to find treatments for difficult to treat diseases such as Alzheimer's, Parkinson's and Schizophrenia."

Asterand plc is a leading supplier of high quality human tissue and tissue-based services.

H. Lundbeck A/S is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders.